Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results

Jenburkt Pharmaceuticals Financial Results

Jenburkt Pharmaceuticals Limited reported its audited financial results for FY 2025-26, alongside a recommended dividend of ₹20.70 (207%) per equity share. The Board also approved the re-appointment of Shri Dilip H. Bhuta as Whole time Director and CFO for a five-year term starting April 2027.

Source

BSE filing, NSE: JENBURPH. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Jenburkt Pharmaceuticals Ltd: key numbers

Share price
₹892.90
Market cap
₹394.1 Cr
Revenue (annual)
₹168.7 Cr
Net profit (annual)
₹34.74 Cr
P/E (TTM)
12.0×Sector 46.1×
Promoter holding
46.62%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Jenburkt Pharmaceuticals Ltd

All →

Other financial results announcements

All →